David E Briles
Overview
Explore the profile of David E Briles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
3365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, An H, Ding M, Liu Y, Wang S, Jin Q, et al.
Sci Transl Med
. 2023 Dec;
15(727):eade0054.
PMID: 38117903
Vaccination has substantially reduced the morbidity and mortality of bacterial diseases, but mechanisms of vaccine-elicited pathogen clearance remain largely undefined. We report that vaccine-elicited immunity against invasive bacteria mainly operates...
2.
Lane J, Tata M, Yasmin R, Im H, Briles D, Orihuela C
mBio
. 2023 Nov;
14(6):e0263423.
PMID: 37982608
is a dangerous human pathogen capable of causing pneumonia and invasive disease. The virulence factor PspA has been studied for nearly four decades with well-established roles in pneumococcal evasion of...
3.
Lane J, Tata M, Yasmin R, Im H, Briles D, Orihuela C
bioRxiv
. 2023 Oct;
PMID: 37808718
() resides in the nasopharynx where it can disseminate to cause disease. One key virulence factor is pneumococcal surface protein A (PspA), which promotes survival by blocking the antimicrobial peptide...
4.
Lane J, Tata M, Briles D, Orihuela C
Front Cell Infect Microbiol
. 2022 Feb;
12:826264.
PMID: 35186799
(), or the pneumococcus, is a Gram-positive bacterium that colonizes the upper airway. is an opportunistic pathogen capable of life-threatening disease should it become established in the lungs, gain access...
5.
Park S, Gonzalez-Juarbe N, Riegler A, Im H, Hale Y, Platt M, et al.
Cell Rep
. 2021 Jun;
35(11):109267.
PMID: 34133917
Streptococcus pneumoniae (Spn) alone and during co-infection with influenza A virus (IAV) can result in severe pneumonia with mortality. Pneumococcal surface protein A (PspA) is an established virulence factor required...
6.
Nakahashi-Ouchida R, Uchida Y, Yuki Y, Katakai Y, Yamanoue T, Ogawa H, et al.
Vaccine
. 2021 May;
39(25):3353-3364.
PMID: 34016473
Current polysaccharide-based pneumococcal vaccines are effective but not compatible with all serotypes of Streptococcus pneumoniae. We previously developed an adjuvant-free cationic nanogel nasal vaccine containing pneumococcal surface protein A (PspA),...
7.
Park S, Gonzalez-Juarbe N, Martinez E, Hale J, Lin Y, Huffines J, et al.
mBio
. 2021 May;
12(3).
PMID: 33947761
Pneumococcal surface protein A (PspA) and pneumococcal surface protein C (PspC, also called CbpA) are major virulence factors of (). These surface-exposed choline-binding proteins (CBPs) function independently to inhibit opsonization,...
8.
Yuki Y, Uchida Y, Sawada S, Nakahashi-Ouchida R, Sugiura K, Mori H, et al.
Mol Pharm
. 2021 Feb;
18(4):1582-1592.
PMID: 33621107
We previously developed a safe and effective nasal vaccine delivery system using a self-assembled nanosized hydrogel (nanogel) made from a cationic cholesteryl pullulan. Here, we generated three pneumococcal surface protein...
9.
Takeda S, Kono M, Sugita G, Arai J, Briles D, Hotomi M
Microb Pathog
. 2021 Feb;
153:104787.
PMID: 33609643
Streptococcus pneumoniae frequently colonizes the human nasopharynx beginning in the early childhood. Pneumococci exhibit a spontaneous and reversible phase shift between opaque and transparent allowing them to adapt to different...
10.
Mukerji R, Briles D
Pediatr Infect Dis J
. 2020 Feb;
39(4):298-304.
PMID: 32032170
Background: Polysaccharide conjugate vaccines (PCVs) target the pneumococcal capsular types that most commonly cause fatal pneumonia and sepsis. Because these types were eliminated by the vaccines, it became apparent that...